Tokyo, Japan – June 22, 2026: SDKI Analytics conducted a survey on the Netherton Syndrome Market, covering key aspects like evolving industry trends, technological advancements, along with market size and share between 2026 and 2035.
Detailed insights from the market research report are available at:
https://www.sdki.jp/reports/netherton-syndrome-market/590642471
Netherton Syndrome Market Report Highlights:
- Report Release Date: June 22, 2026
- Research Organization: SDKI Analytics
- Study Coverage: Global
- Forecast Period: 2026–2035
- Base Year: 2025
- Survey Scope: Our analysts conducted a survey of 510 market players. The size of the players surveyed varied.
- Survey Locations: North America (United States and Canada), Latin America (Mexico, Brazil, Argentina, and Rest of Latin America), Europe (Germany, United Kingdom, France, Italy, Spain, Nordic Countries, and Rest of Europe), Asia Pacific (Japan, China, India, South Korea, ASEAN Countries, Australia, and Rest of Asia Pacific), and Middle East & Africa (GCC, South Africa, North Africa, and Rest of MEA).
- Survey Methodology: 190 on-site surveys, 320 online surveys.
- Survey Period: April 2026 – May 2026
Netherton Syndrome Market Report Scope
This report provides a comprehensive assessment of the Netherton Syndrome market, including:
- Growth Drivers and Restraints
- Emerging Opportunities
- Technological And Regulatory Trends
- Competitive Landscape Analysis
- Market Segmentation Analysis
- Regional And Country-Level Insights, Including Japan
Netherton Syndrome Market Snapshot
According to the latest analysis by SDKI Analytics, the global Netherton Syndrome market size was valued at USD 0.32 billion in 2025 and is projected to reach USD 0.89 billion by 2035, registering a CAGR of 10.8% throughout the forecast period.
As per our analysts, the market is expected to witness substantial growth due to expansion of China’s rare disease diagnosis and treatment network and increasing adoption of genetic testing and precision diagnostics globally.
- Expansion of China’s Rare Disease Diagnosis and Treatment Network: Across Asia‑Pacific, rare disease care is gaining real momentum, and that’s reshaping the outlook for the Netherton syndrome market. A good example is China, where the national rare disease diagnosis and treatment collaboration network has expanded to 419 medical institutions. This expansion means more patients can access specialized care sooner, which in turn supports earlier diagnosis of rare genetic disorders.
The country has further established a rare disease reporting system covering 1.15 billion people, with 1.64 million cases registered to date. This isn’t just about China; it’s a bellwether for the entire region. When a country of China’s size builds out this kind of infrastructure, it creates a template that other Asia-Pacific nations can follow, and that means more patients identified, more clinical trials conducted, and ultimately, a larger addressable market for rare disease therapies.
- Increasing Adoption of Genetic Testing and Precision Diagnostics Globally: According to our SDKI market outlook, the global Netherton Syndrome market growth is also assisted by the rising adoption of genetic testing and precision diagnostics around the world. According to a survey report by the National Library of Medicine, there were 22 clinical genetic tests available for Netherton Syndrome as of 2026.
Improved access to genetic sequencing technologies is elevating early diagnosis and patient identification, enabling enrolment in clinical studies and supporting the development of personalized treatment approaches. As diagnostic capabilities continue to improve, that number is likely to rise, and with it, the patient population eligible for emerging therapies.
Netherton Syndrome Market Recent Industry Developments
According to our research, leading companies operating in the Netherton Syndrome market have recently announced the following developments:
- In June 2026, Quoin Pharmaceuticals announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) granted Orphan Drug Designation to QRX003 for the treatment of Netherton syndrome, while the company continued working with Japanese clinicians on the regulatory pathway toward approval. This milestone strengthens Japan’s rare-disease therapeutic landscape and highlights growing investment in Netherton syndrome diagnosis and treatment development within the Japanese healthcare market.
- In October 2024, BioCryst Pharmaceuticals enrolled the first participant in a Phase 1 clinical trial evaluating BCX17725, a selective KLK5 inhibitor designed as a targeted disease-modifying therapy for Netherton syndrome. The advancement of targeted therapies addressing the underlying cause of Netherton syndrome reflects increasing global research activity and supports growth in the Netherton syndrome treatment market.
Netherton Syndrome Market Segmentation
Our Netherton Syndrome market research segments the market by end user into hospitals, specialty dermatology clinics, academic & research centers, and homecare settings. Of these, the hospitals segment holds the dominant position with a market share of 42%.
Considering how rare diseases are actually managed, the segment is expected to remain lucrative. For instance, Netherton Syndrome is not a condition that a general practitioner encounters every day, or even every year. It requires multidisciplinary care with dermatologists, geneticists, pediatricians, allergists, and nutritionists are all working together.
According to a 2024 survey report covering more than 13,300 respondents across 104 countries by EURORDIS, 25% of rare disease patients consulted more than eight healthcare professionals before even receiving a diagnosis.
Hospitals are positioned to provide this level of coordinated care with their comprehensive departments and access to specialized diagnostic tools. Additionally, Netherton Syndrome patients suffer from severe skin barrier dysfunction, chronic inflammation, and allergic manifestations from infancy, and thus the need of hospital-based care is essential.
Netherton Syndrome Market Regional Overview
According to our analysis of the Netherton Syndrome market, North America is expected to dominate the global landscape, holding the largest market share of approximately 41%. The region’s leadership is driven by its advanced rare disease research ecosystem, robust orphan drug development framework, and early adoption of precision medicine.
What sets North America apart is the depth of its research infrastructure. The NIH’s Rare Diseases Clinical Research Network, with its 21 research consortia and USD 26 million in annual funding, represents a sustained commitment to rare disease research that few other regions can replicate.
This investment creates a virtuous cycle: more research leads to more clinical trials, which leads to more approved therapies, which attracts more investment, which funds more research. And as the epicenter of this ecosystem, North America is where the next generation of Netherton Syndrome therapies, from gene therapies to biologics, are most likely to emerge.
Major players in the Netherton Syndrome Market
As stated in our research report, the most prominent players in the global Netherton Syndrome market are:
- Quoin Pharmaceuticals Ltd.
- Azitra, Inc.
- Castle Creek Biosciences, Inc.
- Krystal Biotech, Inc.
- Amryt Pharma (Chiesi Group)
In addition, the top 5 players in the Japanese market are as follows:
- Maruho Co., Ltd.
- Torii Pharmaceutical Co., Ltd.
- Kyowa Kirin Co., Ltd.
- Mitsubishi Tanabe Pharma Corporation
- Shionogi & Co., Ltd.
Company Profile:
SDKI Analytics’ goal is to provide reliable and in-depth market research and insights. We focus not only on researching and delivering detailed market reports on growth metrics, challenges, trends, and the competitive landscape, but also on completely transforming our clients’ businesses for maximum growth and success. Our market research analysts have extensive experience working with companies of all sizes across various industries and market segments.
Related Reports:
Contact Information:
- Inquiry Form: https://www.sdki.jp/contact/
- Phone number: +81 50 50509337 (9:00-18:00) (excluding weekends and public holidays)
- URL: https://www.sdki.jp/
SDKI Inc. SNS
- X (Twitter): https://twitter.com/SDKIResearch
- Facebook: https://www.facebook.com/sdkiresearch/
